DA 3607

Drug Profile

DA 3607

Alternative Names: DA-3607

Latest Information Update: 20 May 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A ST
  • Class Gene therapies; Nucleosides
  • Mechanism of Action TNF related apoptosis inducing ligand stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Brain cancer

Highest Development Phases

  • Phase I Brain cancer

Most Recent Events

  • 17 Nov 2010 Phase I development is ongoing in South Korea
  • 06 Nov 2009 Phase-I clinical trials in Brain cancer in South Korea (Parenteral)
  • 18 May 2009 DA 3607 is available for licensing in selected territories (http://www.donga-pharm.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top